NCT04359732 (Escape) is a NA clinical trial of hybrid PET/MRI in Esophageal Cancer, sponsored by IRCCS San Raffaele.

Who is sponsoring NCT04359732?

NCT04359732 is sponsored by IRCCS San Raffaele.

What drugs are being tested in NCT04359732?

Interventions in NCT04359732: hybrid PET/MRI.

What condition does NCT04359732 study?

NCT04359732 studies Esophageal Cancer, Esophageal Neoplasms.

Is NCT04359732 still recruiting?

NCT04359732 is currently active, enrolled. Last updated 6 February 2026.

Last reviewed 2026-02-06 · How we verify

NCT04359732: Escape

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessment of Response to nCRT for GEJ Cancer Using a Fully Integrated PET/MRI

Active, enrolled NA Last updated 6 February 2026

What this trial tests

NA trial testing hybrid PET/MRI in Esophageal Cancer in 121 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

8 May 2020

Primary endpoint
2 February 2026

28 February 2026

Quick facts

Lead sponsor	IRCCS San Raffaele
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	121
Start date	8 May 2020
Primary completion	2 February 2026
Estimated completion	28 February 2026
Sites	1 location across Italy

Drugs / interventions tested

hybrid PET/MRI

Conditions studied

Esophageal Cancer — all drugs for Esophageal Cancer →
Esophageal Neoplasms — all drugs for Esophageal Neoplasms →

Sponsor

IRCCS San Raffaele — full company profile →

Who can join

18 and older, any sex, with Esophageal Cancer or Esophageal Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluate the potential role of PET/MRI as a predictor of esophageal and junctional cancers in response to neoadjuvant chemoradiotherapy (nCRT).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Radiomics in the Setting of Neoadjuvant Radiotherapy: A New Approach for Tailored Treatment.
Nardone V, Boldrini L, Grassi R, Franceschini D, et al · · 2021 · cited 24× · PMID 34298803 · DOI 10.3390/cancers13143590
Advancing Esophageal Cancer Staging and Restaging: The Role of MRI in Precision Diagnosis.
Haefliger L, Chapellier P, Vietti Violi N, Ledoux JB, et al · · 2025 · cited 1× · PMID 40282527 · DOI 10.3390/cancers17081351

Verify or expand the search:

Other trials of hybrid PET/MRI

Trials testing the same drug.

NCT03923049 — Feasibility and Accuracy of Hybrid Magnetic Resonance and Positron Emission Tomography With 18F-Fluorodeoxyglucose in Di · NA · terminated

Other recruiting trials for Esophageal Cancer

Currently open trials in the same condition.

NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting

Other IRCCS San Raffaele trials

Trials by the same sponsor.

NCT07454759 — Acute Sarcopenia in Hospitalized Older Adults · not yet recruiting
NCT07456462 — Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance · NA · not yet recruiting
NCT07066878 — This Protocol Focuses on the Factors That Influence Survival, the Development of Complications and the Quality of Life B · not yet recruiting
NCT07526298 — Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Activity in Ap · not yet recruiting
NCT07426471 — Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections. · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04359732 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IRCCS San Raffaele
Last refreshed: 6 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04359732.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing